The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EUZ | -22.72% | -23.37% | -5.18% | +1,409% |
| S&P | +13.95% | +78.35% | +12.25% | +419% |
Eckert & Ziegler Strahlen- und Medizintechnik AG is a holding company, which engages in the provision of isotope technology for medical, scientific, and industrial use. It operates through the following segments: Isotope Products, Medical, and Others. The Isotope Products segment manufactures radiation sources for imaging, measurement technology, quality assurance and environmental monitoring. Its product range extends from calibration sources for advanced medical imaging systems to radiation sources for materials analysis, homeland security, and radiometric level measurements. The Medical segment produces radioactive components for diagnosis and therapy of cancer. The company was founded by Andreas Eckert in 1997 and is headquartered in Berlin, Germany.
No news articles found for Eckert & Ziegler Se.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $75.31M | 7.4% |
| Gross Profit | $34.15M | 0.9% |
| Gross Margin | 45.35% | -2.9% |
| Market Cap | $1.11B | 296.2% |
| Market Cap / Employee | $1.00M | 307.3% |
| Employees | 1.1K | -2.7% |
| Net Income | $8.59M | -9.4% |
| EBITDA | $20.22M | -4.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $120.95M | 23.9% |
| Accounts Receivable | $52.40M | 10.4% |
| Inventory | 46.6 | 2.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $37.04M | -13.2% |
| Short Term Debt | $9.37M | 1.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 8.71% | 0.3% |
| Return On Invested Capital | 13.58% | 0.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $11.10M | -52.6% |
| Operating Free Cash Flow | $18.07M | -31.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 27.87 | 33.59 | 38.78 | 28.04 | -11.81% |
| Price to Book | 1.24 | 1.55 | 2.05 | 4.96 | 336.31% |
| Price to Sales | 3.14 | 3.92 | 4.76 | 3.67 | 9.05% |
| Price to Tangible Book Value | 1.58 | 1.97 | 2.60 | 6.26 | 331.50% |
| Price to Free Cash Flow TTM | 18.80 | 22.10 | 30.28 | 31.24 | 43.36% |
| Enterprise Value to EBITDA | 35.29 | 55.56 | 54.23 | 51.67 | 23.20% |
| Free Cash Flow Yield | 5.3% | 4.5% | 3.3% | 3.2% | -30.25% |
| Return on Equity | 18.0% | 17.5% | 17.6% | 16.9% | 2.27% |
| Total Debt | $55.34M | $53.16M | $48.57M | $46.41M | -10.61% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
